Hostname: page-component-78c5997874-94fs2 Total loading time: 0 Render date: 2024-11-10T15:37:11.932Z Has data issue: false hasContentIssue false
  • English
  • Français

The efficacy of nicorandil, calcium chloride and nitroglycerin in treatment of ropivacaine-induced cardiotoxicity

Published online by Cambridge University Press:  11 July 2005

J. M. Porter ,
F. Markos ,
H. M. Snow  and
G. D. Shorten
J. M. Porter
Affiliation:
University College Cork, Department of Anaesthesia and Intensive Care Medicine, Cork, Ireland
F. Markos
Affiliation:
University College Cork, Department of Physiology, Cork, Ireland
H. M. Snow
Affiliation:
University College Cork, Department of Physiology, Cork, Ireland
G. D. Shorten
Affiliation:
University College Cork, Department of Anaesthesia and Intensive Care Medicine, Cork, Ireland
Get access

Extract

Summary

Background and objective: The amide-linked local anaesthetics, bupivacaine and ropivacaine, can cause depression of cardiac contractility and dysrhythmias. In a previous study, we observed decreased contractility and ST segment depression following ropivacaine administration in anaesthetized dogs. The efficacy of intravenous (i.v.) and intracoronary nicorandil (30 and 100 μg kg−1), i.v. nitroglycerin (glyceryl trinitrate) (5 μg kg−1) and calcium chloride (1, 2 and 4 mmol) in reversing the cardiotoxic effects of intracoronary ropivacaine were studied following the administration of intracoronary ropivacaine.

Methods: Six dogs were studied. The dogs were anaesthetized with i.v. pentobarbital (30 mg kg−1). A left-sided thoracotomy was performed and the left circumflex coronary was cannulated. For each dog, the dose of ropivacaine was identified, which produced measurable cardiotoxicity. In each case, ropivacaine was followed by one of the three resuscitation drugs. The effects of each resuscitation drug on ST segments and left ventricular contractility (dP/dt) produced by ropivacaine alone were compared with those produced by ropivacaine followed by each of the three resuscitation drugs using Fisher's exact test.

Results: The doses of ropivacaine required to produce depression of left ventricular dP/dt and ST segments ranged from 1 to 8 mg. Ropivacaine-induced depression of left ventricular contractility (dP/dt) was more rapidly and completely reversed by calcium chloride than by either nitroglycerin or nicorandil (P = 0.008).

Conclusions: Calcium chloride may be effective in the treatment of inadvertent intravascular administration of amide local anaesthetic agents.

Keywords

ANAESTHETICS, LOCAL, ropivacaineDOGSHEART, myocardiumDRUG TOXICITY, ropivacaineMYOCARDIAL CONTRACTILITY
Type
Original Article
Information
European Journal of Anaesthesiology , Volume 20 , Issue 12 , December 2003 , pp. 939 - 944
Copyright
© 2003 European Society of Anaesthesiology

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Albright GA. Cardiac arrest following regional anaesthesia with etidocaine or bupivacaine. Anesthesiology 1979; 51: 285–287.Google Scholar
Reiz S, Haggmark G, Nath S. Cardiotoxicity of ropivacaine – a new amide local anaesthetic agent. Acta Anaesthesiol Scand 1989; 33: 93–98.Google Scholar
De Jong RH, Davis NL. Treating bupivacaine arrhythmias: preliminary report. Reg Anesth 1981; 6: 99–103.Google Scholar
Kotelko DM, Shnider SM, Dailey PA, et al. Bupivacaine-induced cardiac arrhythmias in sheep. Anesthesiology 1984; 60: 10–18.Google Scholar
Moller R, Covino GG. Cardiac electrophysiological properties of bupivacaine and lidocaine compared to those of ropivacaine, a new amide local anesthetic. Anesthesiology 1990; 72: 322–329.Google Scholar
Clarkson CW, Hondeghem LM. Mechanism for bupivacaine depression of cardiac conduction: fast block of sodium channels during the action potential with slow recovery from block during diastole. Anesthesiology 1985; 62: 392–405.Google Scholar
De La Cousaye JE, Masse C, Bassoul BP, Eledjam JJ, Gagnol JP, Sasine A. Bupivacaine-induced slow-inward current inhibition: a voltage clamp study on frog atrial fibres. Can J Anaesth 1990; 37: 819–822.Google Scholar
Porter JM, Markos F, Snow HM, Shorten GD. Effects of respiratory and metabolic pH changes and hypoxia on ropivacaine-induced cardiotoxicity in dogs. Br J Anaesth 2000; 84: 92–94.Google Scholar
Castle NA. Bupivacaine inhibits the transient outward K+ current but not the inward rectifier in rat myocytes. J Pharmacol Exper Therap 1990; 255: 1038–1046.Google Scholar
Courtney KR, Kendig JJ. Bupivacaine is an effective potassium channel blocker in the heart. Biochim Biophys Acta 1988; 939: 163–166.Google Scholar
Sanchez-Chapula J. Effects of bupivacaine on membrane currents of guinea-pig ventricular myocytes. Eur J Pharmacol 1988; 156: 303–308.Google Scholar
Eledjam JJ, de La Coussaye JE, Brugada J, et al. In vitro study on mechanisms of bupivacaine-induced depression of myocardial contractility. Anesth Analg 1989; 69: 732–735.Google Scholar
Gherardini G, Samuelson U, Jernbeck J, Aberg, Sjostrand N. Comparison of vascular effects of ropivacaine and lidocaine on isolated rings of human arteries. Acta Anaesthesiol Scand 1995; 39: 765–768.Google Scholar
Saitoh K, Hirabayashi Y, Shimizu R, Fukuda H. Amrinone is superior to epinephrine in reversing bupivacaine-induced cardiovascular depression in sevoflurane-anesthetized dogs. Anesthesiology 1995; 83: 127–133.Google Scholar
De La Coussaye JE, Eledjam JJ, Peray P, et al. Mechanisms of the putative cardioprotective effect of hexamethonium in anesthetized dogs given a large dose of bupivacaine. Anesthesiology 1994; 80: 595–605.Google Scholar
Kasten GW, Martin ST. Successful cardiovascular resuscitation after massive intravenous bupivacaine overdosage in anesthetized dogs. Anesth Analg 1985; 64: 491–497.Google Scholar
De La Coussaye, Eledjam JJ, Peray P, et al. Lemakalim, a potassium channel agonist, reverses electrophysiological impairments induced by a large dose of bupivacaine in anaesthetized dogs. Br J Anaesth 1993; 71: 534–539.Google Scholar
Purcell H, Mulcahy D, Fox K. The clinical profile of nicorandil. Rev Contemp Pharmacother 1993; 4: 215–220.Google Scholar
Surtapranata H, MacLeod D. Nicorandil and cardiovascular performance in patients with coronary artery disease. J Cardiovasc Pharmacol 1992; 20: S45–S51.Google Scholar
Tanz RD, Heskett T, Loehning RW, Fairfax CA. Comparative cardiotoxicity of bupivacaine and lidocaine in the isolated perfused mammalian heart. Anesth Analg 1984; 63: 549–556.Google Scholar